Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KerraCel is a gelling fiber wound dressing designed for the management of moderate to heavily exuding chronic and acute wounds. Developed by Crawford Healthcare (now part of 3M), the dressing is composed of 100% carboxymethyl cellulose (CMC) fibers. Upon contact with wound exudate, these fibers transform into a clear, cohesive gel that locks in fluid and harmful components such as bacteria and matrix metalloproteinases (MMPs). This gelling action helps maintain a moist wound healing environment, supports autolytic debridement, and conforms to the wound bed to minimize dead space where bacteria can proliferate. It is primarily indicated for pressure ulcers, leg ulcers, diabetic foot ulcers, and surgical wounds.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on KerraCel.